“Given our role as spokespersons and stakeholders of women with breast cancer, Aifa is obviously one of our interlocutors. We are therefore very happy that Aifa has approved the new indication for this drug.” Rosanna D'Antona, president of Europa Donna Italia, said this on the sidelines of the press conference 'Breast cancer: the new frontiers of treatment', organized in Milan by AstraZeneca and Daiichi Sankyo. At the center of the conference, dedicated to the presentation of new perspectives for the treatment of metastatic breast cancer with low levels of expression of the Her2 receptor, is the monoclonal antibody drug conjugate trastuzumab deruxtecan, whose reimbursement has been approved by Aifa also for this type of patients.
#Breast #cancer #D39Antona #Europa #Donna #spokespersons #patients #breast #cancer
